Active Ingredient: Pacritinib Citrate
Pacnib 100mg is a specialized treatment designed for adults with intermediate-risk or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF, and post-essential thrombocythemia MF. This medication is particularly useful for patients who suffer from very low blood platelet counts (thrombocytopenia). By inhibiting certain enzymes that contribute to the progression of myelofibrosis, Pacnib 100mg helps to reduce symptoms and improve overall health outcomes in these patients.
Indications:
- Intermediate-risk or high-risk Myelofibrosis (MF)
- Primary Myelofibrosis (MF)
- Post-polycythemia vera Myelofibrosis (MF)
- Post-essential thrombocythemia Myelofibrosis (MF)
Mechanism of Action:
Pacnib 100mg works by inhibiting JAK2 and FLT3 enzymes, which play a key role in the abnormal production of blood cells associated with myelofibrosis. This helps in managing symptoms and slowing the progression of the disease, especially in patients with low platelet counts.
Dosage Form: 100mg Tablets
Prescription Requirement:
Pacnib 100mg is available by prescription and is tailored for patients with specific blood and platelet conditions, under the guidance of a healthcare professional.
Advantages of Pacnib 100mg:
-
Effective for Low Platelet Count Patients:
-
Targeted Action:
-
Improves Symptoms:
-
Pacnib 100mg can help reduce the severity of symptoms like spleen enlargement, fatigue, and bone marrow scarring, improving patients rsquo; quality of life.
-
Addresses Multiple Types of Myelofibrosis:
-
It is effective across various forms of myelofibrosis, including primary, post-polycythemia vera, and post-essential thrombocythemia myelofibrosis, offering flexibility in treatment.
-
Oral Administration: